## §8731. Definitions

As used in this subchapter, unless the context otherwise indicates, the following terms have the following meanings. [PL 2019, c. 470, §8 (NEW).]

- 1. Brand-name drug. "Brand-name drug" means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. [PL 2019, c. 470, §8 (NEW).]
- 1-A. Drug product family. "Drug product family" means a group of one or more prescription drugs that share a unique generic drug description and drug form. [PL 2021, c. 305, §1 (NEW).]
- 2. Generic drug. "Generic drug" means a prescription drug, whether identified by its chemical, proprietary or nonproprietary name, that is not a brand-name drug and is therapeutically equivalent to a brand-name drug in dosage, safety, strength, method of consumption, quality, performance and intended use. "Generic drug" includes a biosimilar product. [PL 2019, c. 470, §8 (NEW).]
- 3. Manufacturer. "Manufacturer" means an entity that manufactures or repackages, and sets the wholesale acquisition cost for, prescription drugs that are distributed in the State. [PL 2021, c. 305, §2 (AMD).]
- **3-A.** Prescription drug. "Prescription drug" means a drug, as defined in 21 United States Code, Section 321(g) or a biological product as defined in 42 United States Code, Section 262(i)(1) that:
  - A. Is intended for human use; [PL 2021, c. 305, §3 (NEW).]
  - B. Is not a device within the meaning of 21 United States Code, Section 321(h); and [PL 2021, c. 305, §3 (NEW).]
- C. By federal or state law, can be lawfully dispensed or administered only on prescription by a licensed health care professional. [PL 2021, c. 305, §3 (NEW).] [PL 2021, c. 305, §3 (NEW).]
- 4. Pricing component data. "Pricing component data" means data unique to each manufacturer, wholesale drug distributor or pharmacy benefits manager subject to this subchapter that evidences the cost to each manufacturer, wholesale drug distributor or pharmacy benefits manager to make a prescription drug available to consumers and the payments received by each manufacturer, wholesale drug distributor or pharmacy benefits manager to make a prescription drug available to consumers, taking into account any price concessions, and that is measured uniformly among the entities, as determined by rules adopted by the organization pursuant to section 8737.
- [PL 2019, c. 470, §8 (NEW).]
- 5. Pricing unit. "Pricing unit" means the smallest dispensable amount of a prescription drug that could be dispensed.

[PL 2019, c. 470, §8 (NEW).]

6. Wholesale acquisition cost. "Wholesale acquisition cost" means a manufacturer's listed price for sale to a wholesale drug distributor or other entity that purchases a prescription drug directly from the manufacturer, not including any price concessions.

[PL 2019, c. 470, §8 (NEW).]

SECTION HISTORY

PL 2019, c. 470, §8 (NEW). PL 2021, c. 305, §§1-3 (AMD).

The State of Maine claims a copyright in its codified statutes. If you intend to republish this material, we require that you include the following disclaimer in your publication:

All copyrights and other rights to statutory text are reserved by the State of Maine. The text included in this publication reflects changes made through the First Regular and First Special Session of the 131st Maine Legislature and is current through November 1, 2023. The text is subject to change without notice. It is a version that has not been officially certified by the Secretary of State. Refer to the Maine Revised Statutes Annotated and supplements for certified text.

The Office of the Revisor of Statutes also requests that you send us one copy of any statutory publication you may produce. Our goal is not to restrict publishing activity, but to keep track of who is publishing what, to identify any needless duplication and to preserve the State's copyright rights.

PLEASE NOTE: The Revisor's Office cannot perform research for or provide legal advice or interpretation of Maine law to the public. If you need legal assistance, please contact a qualified attorney.